Skip to content

Ketamine: all studies

Page 293 of 449: studies 2,921 to 2,930 of 4,486, newest first. Back to the ketamine overview

Research

Ketamine as a Fast Acting Antidepressant: Current Knowledge and Open Questions

CNS Neuroscience & Therapeutics April 12, 2013 Giacomo Salvadore, Jaskaran Singh 80 citations

Several recent studies have shown that a single intravenous subanesthetic dose of ketamine, a NMDA receptor antagonist, exerts rapid antidepressant effects in patients with treatment refractory mood disorders and reduces suicidal ideation. Those insights have fueled tremendous excitement in the efforts to elucidate the mechanism underlying ketamine's antidepressant properties in animal models...

Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings)

CNS Neuroscience & Therapeutics April 10, 2013 G. Mion, Thierry Villevieille 690 citations

For more than 50 years, ketamine has proven to be a safe anesthetic drug with potent analgesic properties. The active enantiomer is S(+)-ketamine. Ketamine is mostly metabolized in norketamine, an active metabolite. During "dissociative anesthesia", sensory inputs may reach cortical receiving areas, but fail to be perceived in some association areas. Ketamine also enhances the descending...

DOI: 10.1111/cns.12099 (opens in new tab) Ketamine Nmda receptor Pharmacology Analgesic +8

Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Psychopharmacology March 1, 2013 Lawrence P Carter, Bethea A Kleykamp, Roland R. Griffiths et al. 19 citations

Several studies have documented impairments in memory processes as a result of ketamine administration; however, few studies have compared the profile of cognitive effects of ketamine to other drugs. The aim of this study was to compare the cognitive effects of ketamine with those of triazolam in healthy volunteers. Doses of ketamine (0.2, 0.4 mg/kg intramuscular (i.m.)), triazolam (0.2, 0.4...

DOI: 10.1007/s00213-012-2883-x (opens in new tab) Full text (opens in new tab) Cognitive impairment Memory impairment Cognitive dysfunction Mental decline +28

Ketamine for chronic pain: risks and benefits

British Journal of Clinical Pharmacology February 21, 2013 Marieke Niesters, Christian H. Martini, Albert Dahan 498 citations

The anaesthetic ketamine is used to treat various chronic pain syndromes, especially those that have a neuropathic component. Low dose ketamine produces strong analgesia in neuropathic pain states, presumably by inhibition of the N-methyl-D-aspartate receptor although other mechanisms are possibly involved, including enhancement of descending inhibition and anti-inflammatory effects at central...

Long-Lasting Antidepressant Action of Ketamine, but Not Glycogen Synthase Kinase-3 Inhibitor SB216763, in the Chronic Mild Stress Model of Mice

PLoS One February 4, 2013 Xiancang Ma, Yonghui Dang, Min Jia et al. 115 citations

BACKGROUND: Clinical studies demonstrate that the N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, induces rapid antidepressant effects in patients with refractive major depressive disorder and bipolar depression. This rapid onset of action makes ketamine a highly attractive drug for patients, particularly those who do not typically respond to therapy. A recent study suggested that...

DOI: 10.1371/journal.pone.0056053 (opens in new tab) Ketamine Tail suspension test Pharmacology Behavioural despair test +11

Ketamine for the Treatment of Depression

Journal of Psychosocial Nursing and Mental Health Services 2013 Robert H Howland

Ketamine (Ketalar®) is an anesthetic agent derived from the hallucinogenic drug phencyclidine (PCP). It is a high-affinity antagonist at N-methyl-D-aspartate receptors and also binds to opioid mu and sigma receptors. Ketamine is being intensively investigated as an antidepressant therapy. To date, five short-term controlled studies and other open-label studies in patients with unipolar or...

Differential behavioral effects of ketamine between adolescent and adult Sprague-Dawley rats

VCU Scholars Compass 2013 Maria A. Greenwood 1 citation

The dissociative anesthetic ketamine has been subject to growing abuse worldwide, particularly in adolescents. This project compared the effects of ketamine in conditioned place preference and intravenous self-administration in adolescent (PND 28-50) and adult (>PND70) Sprague-Dawley rats. Cocaine served as a positive control. In CPP, adolescents demonstrated preferences for ketamine, while...

Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment.

Journal of Neuroscience October 3, 2012 Miriam Kron, C James Howell, Ian T Adams et al.

Excitatory-inhibitory imbalance has been identified within specific brain microcircuits in models of Rett syndrome (RTT) and other autism spectrum disorders (ASDs). However, macrocircuit dysfunction across the RTT brain as a whole has not been defined. To approach this issue, we mapped expression of the activity-dependent, immediate-early gene product Fos in the brains of wild-type (Wt) and...

Ketamine bladder syndrome: an important differential diagnosis when assessing a patient with persistent lower urinary tract symptoms.

BMJ Case Reports September 30, 2012 Shalom Srirangam, Joe Mercer

The recreational use of ketamine is increasing in popularity due to its dissociative and paralytic effects, ease of availability and low cost. However, serious and frequently irreversible damage to the urinary tract is a recently recognised side effect of recreational ketamine use. The authors present a case of a young male patient with a 2-year history of troublesome lower urinary tract...

DOI: 10.1136/bcr-2012-006447 (opens in new tab) Full text (opens in new tab) Ketamine Humans Substance-related disorders Diagnosis, differential +3

Ketamine Decreases Resting State Functional Network Connectivity in Healthy Subjects: Implications for Antidepressant Drug Action

PLoS One September 24, 2012 Milan Scheidegger, Martin Walter, Mick Lehmann et al. 282 citations

Increasing preclinical and clinical evidence underscores the strong and rapid antidepressant properties of the glutamate-modulating NMDA receptor antagonist ketamine. Targeting the glutamatergic system might thus provide a novel molecular strategy for antidepressant treatment. Since glutamate is the most abundant and major excitatory neurotransmitter in the brain, pathophysiological changes in...